SL-101, a Novel Monoclonal Antibody-Conjugate That Targets Interleukin-3 Receptor Alpha (CD123), Possesses Preclinical Anti-Tumor Activity Against Hodgkin's Lymphoma
SL-101, A Novel Monoclonal Antibody-Conjugate That Targets Interleukin-3…
SL-401, A Targeted Therapy Directed to the Interleukin-3 Receptor Present On Leukemia Blasts and Cancer Stem Cells, Is Active As a Single Agent in Patients with Advanced AML. ASH 2012.
SL-401, A Targeted Therapy Directed to the Interleukin-3 Receptor Present On…
A Pilot Study of Peptide-Based Vaccines in Combination With Poly ICLC in Patients With WHO Grade 2 Low-Grade Glioma
A pilot study of peptide-based vaccines in combination with poly ICLC in…
The IL-3Rα-Targeted Drug SL-401 Selectively Kills Blastic Plasmacytoid Dendritic Cell Neoplasm Cells. ASH 2011.
The IL-3Rα-Targeted Drug SL-401 Selectively Kills Blastic Plasmacytoid…
Hodgkin's Lymphoma Cell Lines Have Up-Regulated IL-3 Receptor α (IL-3Rα) Expression and Are Sensitive to SL-401, an IL-3Rα-Targeted Drug
Hodgkin’s Lymphoma Cell Lines Have Up-regulated IL-3 Receptor α (IL-3Rα)…
Phase I/II Vaccine Study Targeting Novel HLA-A2-Restricted CTL Epitopes in Combination With Poly-ICLC in Patients With Recurrent Malignant Glioma
Phase I/II vaccine study targeting novel HLA-A2-restricted CTL epitopes in…